Dirk Smeesters, the former psychology professor at Erasmus University found to have committed misconduct, has had another paper retracted.
Here’s the notice: Continue reading Retraction four appears for Dirk Smeesters
Category: by publisher
Harvard and the Brigham investigating leading heart group for “compromised” data
Circulation has retracted a 2012 study by a group of Harvard heart specialists over concerns of corrupt data, and the university is investigating. The group was led by Piero Anversa, a leading cardiologist, and Joseph Loscalzo — who will be familiar to readers of Circulation as the editor in chief of that journal. (Anversa’s also on the editorial board).
Continue reading Harvard and the Brigham investigating leading heart group for “compromised” data
Double taxation: Journal retracts paper it published twice
International Studies Quarterly, a Wiley title, is retracting a paper because — oops! — it published the same article twice, unbeknownst to the authors.
Here’s the notice: Continue reading Double taxation: Journal retracts paper it published twice
Pain study retracted for bogus data is second withdrawal for University of Calgary group
Back in January 2013, we wrote about the retraction of a paper in Diabetes that the authors had “submitted without knowledge of inherent errors or abnormalities that they recognized in retrospect after submission.”
Now, Molecular Pain has retracted a paper by the same authors, this time for data manipulation. The article, “Comparison of central versus peripheral delivery of pregabalin in neuropathic pain states,” was written by Cory Toth, a clinical neuroscientist at the University of Calgary, in Canada, and colleagues. It has been cited eight times, according to Thomson Scientific’s Web of Knowledge.
Toth said of the Diabetes article at the time:
Continue reading Pain study retracted for bogus data is second withdrawal for University of Calgary group
Erratum appears for Ulrich Lichtenthaler, who has 13 retractions
Ulrich Lichtenthaler, the management professor who has had 13 papers retracted, has a correction in the Journal of Product Innovation Management.
Here’s the text of the correction for “The Role of Champions in the External Commercialization of Knowledge, ” which is followed by the corrected tables: Continue reading Erratum appears for Ulrich Lichtenthaler, who has 13 retractions
Do you see what I see? Heart imaging journal yanks cardiac study for plagiarism
The International Journal of Cardiovascular Imaging has retracted a 2013 paper by a group of researchers from Italy. The reason: plagiarism.
The paper was titled “Diagnostic accuracy of 320-row computed tomography as compared with invasive coronary angiography in unselected, consecutive patients with suspected coronary artery disease,” and it came from scientists in Rome led by Francesco Pelliccia of the Department of Heart and Great Vessels at Sapienza University.
Continue reading Do you see what I see? Heart imaging journal yanks cardiac study for plagiarism
MS paper second to fall following University of Queensland investigation
Two former University of Queensland researchers have lost another paper following an investigation into their work.
In September, the university announced that a paper in the European Journal of Neurology by Bruce Murdoch and Caroline Barwood would be retracted because
no primary data can be located, and no evidence has been found that the study described in the article was conducted.
The university continued its investigation, and announced today that: Continue reading MS paper second to fall following University of Queensland investigation
Late resveratrol researcher Dipak Das manages to revise and publish paper from the grave
Follow this timeline, if you would:
- August 14, 2013: Former UConn researcher Dipak Das, who was found to have committed misconduct, submits a paper to Oxidative Medicine and Cellular Longevity.
- September 19, 2013: Das dies.
- October 17, 2013: Das submits revisions to his paper in Oxidative Medicine and Cellular Longevity.
- October 18, 2013: Paper accepted.
- January 12, 2014: Paper published.
That would appear to be what the timeline on the paper — which lists Das as corresponding author, along with a Gmail address — says:
First retraction appears for Dutch anthropologist Mart Bax
Last September we wrote about the case of Mart Bax, an anthropologist once of the Free University in Amsterdam who allegedly fabricated elements in some of his papers, and claimed to have written more than 60 that do not exist:
Bax, who studied an Irish town he called Patricksville, a Dutch pilgrimage site he called Neerdonk, and Medjugorje, a Bosnian pilgrimage site, retired from the Free University in 2002. The university began investigating Bax’s work last year after science journalist Frank van Kolfschooten published Ontspoorde Wetenschap (“Derailed science”). In that book, van Kolfschooten raised questions about Bax’s work into an alleged massacre at Medjugorje during the Bosnian War. Bax responded to those questions in April of this year.
Here’s the university’s 67-page report, in Dutch. The university will not take legal action against Bax. It is unclear from the translations we’ve seen whether any of the papers will be retracted, but we’ll update with anything we learn.
Well, at least part of that ambiguity has cleared, with the retraction of a 2000 paper by Bax in Ethnic and Racial Studies. The article was titled “Warlords, priests and the politics of ethnic cleansing: a case-study from rural Bosnia Hercegovina” and has been cited 20 times, according to Thomson Scientific’s Web of Knowledge. Here’s its abstract: Continue reading First retraction appears for Dutch anthropologist Mart Bax
Novartis Diovan scandal claims two more papers
A complicated story involving Novartis’s valsartan (Diovan) has led to the retraction of two more papers, one cascading from the other.
Last September, The Lancet retracted the Jikei Heart Study after a slew of retractions of related work prompted an investigation of valsartan research. That investigation found evidence of data manipulation and the failure of one researcher to note his Novartis affiliation. The company has apologized.
Here’s one retraction, from Diabetes Care, for “The Shiga Microalbuminuria Reduction Trial (SMART) Group. Reduction of Microalbuminuria in Patients With Type 2 Diabetes: The Shiga Microalbuminuria Reduction Trial (SMART):”
Continue reading Novartis Diovan scandal claims two more papers